相关实验视频

Updated: Jul 5, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

对EGFR突变检测的模拟分析:康胺Dx标测试和AmoyDx面板对肺癌治疗决策的影响

Yosuke Hirotsu¹, Takahiro Nakagomi², Yuki Nagakubo³

¹Genome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, 400-8506, Japan. hirotsu-bdyu@ych.pref.yamanashi.jp.

Scientific reports

|January 18, 2024

概括

这项研究比较了两个EGFR突变测试的非小细胞肺癌 (NSCLC). 这两种测试都能有效地检测出可操作的突变,但Oncomine Dx目标测试 (ODxTT) 显示了对EGFR突变的覆盖范围略为广泛.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
分子诊断学分子诊断学

背景情况:

肺癌仍然是全球癌症死亡的主要原因之一.
表皮生长因子受体 (EGFR) 突变是非小细胞肺癌 (NSCLC) 向治疗的关键生物标志物.
伴随诊断 (CDx) 测试对于识别这些突变和指导治疗选择至关重要.

研究的目的:

评估和比较两种CDx测试的性能,即Oncomine Dx目标测试 (ODxTT) 和AmoyDx胰腺肺癌PCR小组,用于检测NSCLC患者的EGFR突变.
评估EGFR突变检测差异对向疗法的适用性的影响.

主要方法:

利用了来自127名EGFR突变NSCLC患者的282个样本的内部定向测序数据集.
对EGFR变异的ODxTT和AmoyDx面板之间的模拟一致性分析.
评估检测到的EGFR突变的致癌性和治疗潜力.

主要成果:

在已识别的216个EGFR突变中,51%被两种CDx测试检测出来,3%仅通过ODxTT检测出来,46%没有被检测出来.
大多数非向突变缺乏致癌性,并且位于关键外因子 (18-21) 外.
通过这两种测试检测到的突变中有95%是致癌的;可操作的EGFR突变中有97%被这两种测试覆盖,仅ODxTT就有1%.

结论:

无论是ODxTT还是AmoyDx都有效地检测出NSCLC中几乎所有可操作的EGFR突变.
与AmoyDx面板相比,ODxTT提供了对EGFR突变的稍微更全面的覆盖.
选择合适的CDx测试对于优化EGFR阳性NSCLC治疗决策至关重要.

更多相关视频

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...